Payment & Shipping Terms:
|CAS:||357336-20-0||Apparence:||Almost White Crystalline Powder|
|Purity:||99.5%||Main Usage:||Brain Health Drug|
|Grade:||Pharma Grade||Stock:||Enough Stock|
Brivaracetam Briviact CAS 357336-20-0 Active Pharmaceutical Ingredients Powder
Product Name : Brivaracetam ; (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide;UCB-34714
CAS No. 357336-20-0
Molecular Formula C11H20N2O2
Molecular Weight 212.29
Appearance White off-white crystalline powder
Grade Standard Medicine Grade
Appearance White crystal or crystalline powder
Storage Store in well-closed container, protec...
The precise mechanism by which brivaracetam exerts its antiepileptic activity is unknown. Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the antiepileptic effect.
Brivaracetam is a prescription medication used with other medicines to treat partial-onset seizures in people 16 years of age and older with epilepsy. Brivaracetam belongs to a group of drugs called antiepileptics. These work by reducing the frequency of seizures.
This medication comes in a tablet and solution form and is usually taken 2 times a day by mouth with or without food. The brivaracetam tablets should be swallowed whole with liquid. Do not crush or chew brivaracetam tablets before swallowing.
This medication is also available in an injectable form to be given directly into a vein (IV) by a healthcare professional.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Briviact: 50 mg/5 mL (5 mL)
Briviact: 10 mg/mL (300 mL) [contains methylparaben; raspberry flavor]
Briviact: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg
Half-Life Elimination About~9 hours
Protein Binding ≤20% to plasma proteins
Brivaracetam Dosing: Adult
Partial onset seizures: Oral, IV: Initial: 50 mg twice daily; may decrease to 25 mg twice daily or increase up to 100 mg twice daily based on individual patient response and tolerability (maximum: 200 mg/day). Note: Use injection when oral administration is temporarily not feasible; clinical study experience with brivaracetam injection is limited to 4 consecutive days of treatment.
Dosage adjustment for concomitant therapy with rifampin: Increase brivaracetam dosage by up to 100% (ie, double the brivaracetam dose).
Discontinuation of therapy: Reduce gradually; it has been recommended to reduce the dose by 50 mg/day on a weekly basis with the final week of treatment at the dose of 20 mg/day (Brivlera Canadian product labeling 2016).
|Refer to adult dosing. Consider starting at the low end of the dosage range.|
|Partial onset seizures: Adolescents ≥16 years: Oral, IV: Refer to adult dosing.|
Dosing: Renal Impairment
Mild to severe impairment: No dosage adjustment necessary.
End-stage renal disease requiring dialysis: Use is not recommended (has not been studied).
Dosing: Hepatic Impairment
|Mild to severe impairment (Child Pugh classes A, B, and C): Initial: 25 mg twice daily, up to a maximum of 75 mg twice daily.|
Injection: Administer IV over 2 to 15 minutes; may administer undiluted or diluted with NS, LR, or D5W.
Oral solution: Administer with or without food. Use a calibrated measuring device to measure (household teaspoon or tablespoon is not an adequate measuring device). May also be administered using a nasogastric tube or gastronomy tube.
Tablets: Administer with or without food. Swallow tablets whole with liquid; do not chew or crush.
How to take and store Brivaracetam?
Taking medicine: It's important to take any seizure medication the same way every day.
Using the oral solution:
Remembering medicine: Since missing doses of seizure medications can lead to breakthrough seizures, use reminders to help you avoid missing doses. Examples of reminders may include:
Brivaracetam Adverse Reactions
Frequency not always defined.
Central nervous system: Fatigue (≤20% to ≤27%; dose-dependent), hypersomnia (≤20% to ≤27%; dose-dependent), lethargy (≤20% to ≤27%), malaise (≤20% to ≤27%; dose-dependent), drowsiness (≤16% to ≤27%; dose-dependent), sedation (≤16% to ≤27%; dose-dependent), dizziness (12% to ≤16%), equilibrium disturbance (≤3% to ≤16%), abnormal gait (≤16%), ataxia (≤16%), vertigo (≤16%), psychiatric disturbance (13%; includes psychotic and nonpsychotic), euphoria (IV: ≥3%), feeling drunk (IV: ≥3%), infusion-site pain (IV: ≥3%), irritability (3%), suicidal ideation
Gastrointestinal: Nausea and vomiting (5%), dysgeusia (IV:≥3%), constipation (2%)
Hematologic & oncologic: Decreased white blood cell count (2%)
Hypersensitivity: Hypersensitivity reaction
Neuromuscular & skeletal: Weakness (≤20% to ≤27%)
Ophthalmic: Nystagmus (≤16%)
<1% (Limited to important or life-threatening): Angioedema, bronchospasm, decreased neutrophils